News | Stents Drug Eluting | February 16, 2022

Elixir Medical Completes Enrollment in Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Trial is evaluating DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance.

Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System,

DynamX Coronary Bioadaptor System


February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance.

The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 35 centers in Japan, Europe and New Zealand treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure (TLF) at one year. Secondary endpoints include measures of the implant’s ability to accommodate vessel growth from disease progression and restore vessel pulsatility in an imaging subset, as well as the incidence of major cardiovascular events.

“The bioadaptor is a revolutionary innovation in percutaneous coronary intervention and we are enthusiastic about studying the device’s ability to accommodate and restore vessel movement and function,” said Shigeru Saito, MD, Director of the Cardiology and Catheterization Laboratory at Shonan Kamakuru General Hospital, Kanagawa, Japan, and principal investigator of the BIOADAPTOR RCT. “Despite the challenges presented by the COVID pandemic, we are proud that we were able to enroll the trial in about one year.”

The DynamX Bioadaptor is designed to address the continuous major adverse cardiac event rate that occurs with drug-eluting stents (DES) each year without plateau.1,2,3 The rigid design of a DES constrains, or “cages,” natural artery functions, restricting its ability to expand, contract and rotate with each heartbeat, as well as accommodate disease progression. This has been associated with major adverse cardiac events (MACE).4 Long-term studies have shown adverse event rates associated with DES of 20 percent at five years and 40 to 50 percent at 10 years.2 Clinical studies have demonstrated that a DES prevents positive adaptive remodeling,5 inhibits vessel pulsatility and dilation in response to the body’s changing blood flow needs,6,7 and causes vessel straightening, which has been associated with increased MACE.8

By incorporating unique “uncaging elements” in its metallic implant design, the DynamX Bioadaptor allows for the restoration of natural artery function and movement9 essential to cardiovascular performance. The DynamX Bioadaptor is designed to improve clinical outcomes by adapting to vessel physiology and restoring positive adaptive remodeling, pulsatility and rotation.

The DynamX Bioadaptor supports the coronary artery with radial strength and acute performance similar to DES during healing. The drug-eluting polymer coating resorbs over six months and the device then “uncages,” allowing the artery to move naturally in response to the body’s needs.

The DynamX Coronary Bioadaptor System is CE Mark approved.  Not available for sale in the USA.

For more information: elixirmedical.com/us/

Also read First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

 References:

  1. Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8(6):e002230. doi:10.1161/CIRCINTERVENTIONS.114.002230
  2. Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: results from the ISAR-TEST 4 randomized trial. Circulation2019; 139:325–333. doi: 10.1161/CIRCULATIONAHA.118.038065.
  3. Smits, PC, Valchojannis, GJ, McFadden, EP, et al. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice. J Am Coll Cardiol Intv. 2015 Aug, 8 (9) 1157-1165.
  4. Stone GW, Kimura T, Gao R, et al. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled StudyJAMA Cardiol. 2019;4(12):1261–1269. doi:10.1001/jamacardio.2019.4101
  5. Nakamura M, Yock PG, Bonneau HN, et al. Impact of peri-stent remodeling on restenosis: a volumetric intravascular ultrasound study. Circulation. 2001;103(17):2130-2132. doi:10.1161/01.cir.103.17.2130
  6. Maier, W, Windercker, S, Kung, A, et al. Exercise-Induced Coronary Artery Vasodilation Is Not Impaired by Stent Placement. Circulation. 2002; 105(20): 2373-2377. doi: 10.1161/01.cir.0000016360.97819.44
  7. Hamilos, M, Sarma, J, Ostojic, M, et al. (2008). Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion Evidence for Device-Specific Responses. Circulation. Cardiovascular interventions. 1. 193-200. 10.1161/CIRCINTERVENTIONS.108.797928.
  8. Gyöngyösi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol. 2000;35(6):1580-1589. doi:10.1016/s0735-1097(00)00570-2
  9. Verheye S, Vrolix M, Montorfano M, Zivelonghi C, Giannini F, Bedogni F, et al. Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor. EuroIntervention 2020;16;e974-e981
  10. Kansal, M, Wolska B, Verheye, S, Vidovich, M.  Adaptive coronary artery rotational motion through uncaging of a drug-eluting bioadaptor aiming to reduce stress on the coronary artery,  Cardiovascular Revascularization Medicine, 2021.

Related Content

News | Stents

June 12, 2024 — Royal Philips, a global leader in health technology, announced the first implant of the Duo Venous Stent ...

Home June 12, 2024
Home
News | Stents

June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and ...

Home June 04, 2024
Home
News | Stents

April 17, 2024 — Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered ...

Home April 17, 2024
Home
News | Stents

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
News | Stents

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

Home January 23, 2023
Home
Subscribe Now